Remimazolam Tosylate

甲苯磺酸瑞马唑仑

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameRemimazolam Tosylate
Drug Alias NameRemimazolam tosilate甲苯磺酸瑞米唑仑瑞倍宁HR-7056
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsSedationSubstance-Related DisordersPain +[6] 
Global Approved IndicationsSedation
Approved Indications in ChinaSedation
Original Approved Country/TerritoryMainland China
Original Approved Date2019/12/26
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNational Institute Of General Medical SciencesThe First Affiliated Hospital Of Kunming Medical UniversitySun Yat-Sen University +[6] 
Inactive CompaniesPaion Uk LtdSoutheast UniversityFujian Suncadia Medicine Co Ltd
Active IndicationsSedationPainPostoperative Cognitive Complications +[5] 
Inactive IndicationsSubstance-Related Disorders

Other Information

ATC CodeN05CD14
Related LinksDrugBank